ReviewBiomarker research2017
Diagnosis and treatment of CD20 negative B cell lymphomas.
Review in Biomarker research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- CD20 negativity at the start of second-line therapy predicts a shorter overall survival in B-cell lymphomas.Blood neoplasia · 2026Article
- Primary Breast Lymphoplasmacytic Lymphoma in a Young Woman: A Rare Case of Waldenström's Disease.Cureus · 2025Article
- Primary adrenal CD20-negative diffuse large B-cell lymphoma: Diagnostic and therapeutic challenges-A case report.Radiology case reports · 2025Article
- CD20-Negative Primary Bone Marrow Large B Cell Lymphoma: A Report of Two Cases with Review of Literature.South Asian journal of cancer · 2025Article
- N-terminal truncation of STAT1 transcription factor causes CD3- and CD20-negative non-Hodgkin lymphoma through upregulation of STAT3-mediated oncogenic functions.Cell communication and signaling : CCS · 2025Article
- Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma.Annals of hematology · 2025Article
- Article
- Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.Journal of hematology · 2024Article
- Cluster of Differentiation Markers and Human Leukocyte Antigen Expression in Chronic Lymphocytic Leukemia Patients: Correlations and Clinical Relevance.Current issues in molecular biology · 2024Article
- Review
- Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.Theranostics · 2024Review
- Promising immunotherapeutic approaches for primary effusion lymphoma.Exploration of targeted anti-tumor therapy · 2024Review
- EBV Positive Diffuse Large B Cell Lymphoma with Negative Pan-B Cell Markers, Case Report, and Literature Review.Case reports in hematology · 2024Article
- Overview of Molecular Diagnostics in Irish Clinical Oncology.HRB open research · 2024Article
- BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report.Oncology letters · 2023Article
- [Chinese consensus on the diagnosis and management of Epstein-Barr virus-related post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma.Antibodies (Basel, Switzerland) · 2022Article
- Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.Mediterranean journal of hematology and infectious diseases · 2022Article
- CD-20 Negative Plasmablastic Lymphoma Lurking in the Shadow of a Leiomyoma - Diagnosis and Management.Cureus · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman's disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.